
    
      To determine the disease free survival and overall survival of patients with ALL and ANLL
      after induction failure, in relapse, or subsequent remission from CML in several phases or
      recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide
      followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated
      Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by
      Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade
      Lymphoma
    
  